Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

AIMS: Two phase 1, open‐label studies were conducted to investigate the effect of renal impairment (RI) and organic anion transporter (OAT) inhibition on pharmacokinetics (PK) and safety of relebactam (REL) plus imipenem/cilastatin (IMI). METHODS: Study PN005 evaluated the PK of REL (125 mg) plus IM...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Bhagunde, Pratik, Colon‐Gonzalez, Francheska, Liu, Yang, Wu, Jin, Xu, Shiyao Sherrie, Garrett, Graigory, Jumes, Patricia, Lasseter, Kenneth, Marbury, Thomas, Rizk, Matthew L., Lala, Mallika, Rhee, Elizabeth G., Butterton, Joan R., Boundy, Keith
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7163372/
https://ncbi.nlm.nih.gov/pubmed/31856304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14204
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky